India to continue to allow the sale of Ranitidine, a drug under scrutiny for potential cancer risks due to NDMA impurities.

In a footnote of his opinion, Judge Joshua Roberts wrote, “A more cynical view of the circumstances is that plaintiffs’ ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

Health authorities say there is no immediate risk, but patients have been advised to consult a doctor who can prescribe alternatives to ranitidine. On 13 September, both the US Food and Drug ...

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.